论文部分内容阅读
目的探讨康莱特注射液对食管鳞癌患者副反应、免疫功能和化疗疗效的影响。方法 98例食管鳞癌患者分为实验组和对照组,每组49例,对照组采用“5-氟尿嘧啶+顺铂”或“紫杉醇+顺铂”方案化疗,实验组在化疗的基础上加用康莱特注射液。结果对照组和实验组化疗有效率差异无统计学意义(P>0·05),实验组严重消化道反应、严重骨髓抑制和乏力的发生率显著低于对照组(P<0·05)。对照组和实验组化疗前后CD3+和CD8+差异无统计学意义(P>0·05)。对照组化疗后CD4+T细胞百分数减少,CD4+T细胞/CD3+T细胞比值降低(P<0·05);实验组化疗后CD4+T细胞百分数增高,CD4+T细胞/CD3+T细胞比值增高(P<0·05)。结论康莱特注射液可以减轻食管鳞癌化疗的副反应,提高患者的免疫能力。
Objective To investigate the effect of Kanglaite Injection on the side effects, immune function and chemotherapy in patients with esophageal squamous cell carcinoma. Methods 98 cases of esophageal squamous cell carcinoma patients were divided into experimental group and control group, 49 cases in each group. The control group received chemotherapy with 5-fluorouracil plus cisplatin or paclitaxel plus cisplatin. Based on the addition of Kanglaite injection. Results There was no significant difference in the effective rate of chemotherapy between the control group and the experimental group (P> 0.05). The incidences of severe gastrointestinal reactions, severe myelosuppression and fatigue in the experimental group were significantly lower than those in the control group (P <0.05). There was no significant difference in CD3 + and CD8 + between the control group and the experimental group before and after chemotherapy (P> 0.05). The percentage of CD4 + T cells decreased and the ratio of CD4 + T cells / CD3 + T cells decreased in the control group after chemotherapy (P <0.05). The percentage of CD4 + T cells increased in the experimental group after chemotherapy, and the percentage of CD4 + T cells / CD3 + T cells The ratio increased (P <0 · 05). Conclusion Kanglaite injection can reduce the side effects of esophageal squamous cell carcinoma chemotherapy and improve the patient’s immune capacity.